CROs may support many assay categories, including biochemical assays, biophysical assays, cell-based assays, phenotypic assays, immunoassays, bioanalytical assays, ADME/PK assays, toxicology assays, analytical and CMC assays, potency assays, pharmacopeial assays, genomics assays, biomarker assays, microbiology assays, and high-throughput screening assays. However, no CRO is equally strong in every assay type. Assay quality depends on the molecule, therapeutic area, biological question, sample type, matrix, assay format, detection technology, controls, validation expectations, data-analysis method, and intended use of the result. Choosing a CRO only because it lists a service name can lead to weak data, repeated experiments, misleading interpretation, poor comparability, delayed development decisions, and wasted budget. InnoEco is designed to help Project Sponsors compare CRO partners by structured assay capabilities, technical expertise, scientific fit, and project context, not only by generic service categories.
CROs cover a wide range of assays, but that does not mean every CRO is the right partner for every assay.
This distinction is important.
In biotech and pharma outsourcing, the word assay can mean a simple measurement, a complex biological system, a high-throughput screen, a validated analytical procedure, a potency method, a toxicology endpoint, a biomarker readout, or a CMC release test. Two CROs may both claim they offer “cell-based assays” or “bioanalysis,” while their real strengths, platforms, controls, quality systems, and disease-area experience are very different.
For Project Sponsors, the risk is not only choosing a CRO that cannot run the assay. The larger risk is choosing a CRO that can run something with the same name, but not the assay needed for the sponsor’s molecule, modality, therapeutic area, development stage, or data-use case.
That is how outsourcing projects generate data that exist, but do not answer the question.
Why Assay Choice Is a High-Risk Decision
Assays convert biology, chemistry, and product quality into data. If the assay is wrong, weak, poorly controlled, or mismatched to the project, the downstream decision becomes unreliable.
A poor assay choice can create several consequences:
| Assay problem | Possible consequence |
|---|---|
| Wrong assay format | The data do not reflect the biological mechanism or product attribute of interest. |
| Wrong sample matrix | Interference, poor recovery, matrix effects, or misleading quantification. |
| Wrong detection technology | Weak sensitivity, poor dynamic range, high background, or low reproducibility. |
| Weak controls | The sponsor cannot distinguish a true signal from noise or artifact. |
| Incomplete validation or qualification | Data may not be suitable for the intended decision. |
| Poor disease or modality fit | The CRO may understand the assay platform but not the therapeutic context. |
| Poor data package | Results may be hard to interpret, compare, reproduce, or use in downstream work. |
| Wrong CRO specialization | The provider may be strong in one assay family but weak in the specific assay required. |
This is why assay selection should not be treated as a purchasing step. It is part of scientific strategy.
CROs Cover Many Assay Categories, But Categories Are Not Enough
A CRO service catalog may include dozens or hundreds of assays. The categories below are common across discovery, preclinical, analytical, translational, CMC, and clinical-support outsourcing.
| Assay category | Common examples | Why CRO specialization matters |
|---|---|---|
| Biochemical assays | Enzyme activity, binding, inhibition, substrate turnover, reporter-free activity assays | Small changes in buffer, substrate, cofactors, incubation time, or detection chemistry can change the result. |
| Biophysical assays | SPR, BLI, ITC, DSF, MST, DLS, SEC-MALS, thermal shift assays | These methods require expertise in protein quality, binding kinetics, aggregation, nonspecific binding, and data fitting. |
| Cell-based assays | Reporter assays, viability, proliferation, cytotoxicity, pathway activation, receptor signaling | Cell line, passage number, expression level, stimulation condition, and readout timing can strongly affect interpretation. |
| Phenotypic assays | Imaging, morphology, migration, invasion, organoids, spheroids, co-culture models | Biological relevance is higher, but complexity, variability, and analysis burden increase. |
| Immunoassays | ELISA, MSD, Luminex, HTRF, AlphaLISA, cytokine panels, ligand-binding assays | Matrix effects, antibody specificity, standard curve quality, and cross-reactivity can dominate data quality. |
| Bioanalytical assays | LC-MS/MS, ligand-binding assays, PK assays, ADA assays, biomarker quantification | Method validation, matrix selection, calibration, sample stability, and intended regulatory use matter. |
| ADME and DMPK assays | Microsomal stability, plasma protein binding, permeability, CYP inhibition, transporter assays, metabolite ID | Results depend on species, matrix, compound properties, analytical method, and study design. |
| Toxicology and safety assays | In vitro toxicity, genotoxicity, safety pharmacology, cytokine release, tissue pathology endpoints | CRO expertise must match species, modality, endpoint, and documentation expectation. |
| Analytical and CMC assays | HPLC, UPLC, SEC-HPLC, CE-SDS, icIEF, mass spectrometry, impurity testing, stability testing | Method suitability, product knowledge, reference standards, and quality expectations are critical. |
| Potency assays | Cell-based potency, binding potency, neutralization, enzyme activity, receptor activation | Potency assays are often product-specific and may require biological relevance plus precision. |
| Pharmacopeial assays | USP, Ph. Eur., JP, or other compendial tests where applicable | These assays may require compendial method understanding, verification, validation, and documentation discipline. |
| Genomics and multi-omics assays | WES, WGS, RNA-seq, scRNA-seq, metagenomics, proteomics, metabolomics | Data quality depends on sample quality, library method, platform, bioinformatics pipeline, QC, and interpretation. |
| Biomarker assays | Translational biomarkers, pharmacodynamic markers, exploratory or validated biomarker readouts | Context matters: exploratory discovery, patient stratification, pharmacodynamics, and clinical-support assays are different. |
| Microbiology and infectious disease assays | Sterility, endotoxin, microbial limits, antimicrobial activity, viral assays, pathogen detection | Method selection, controls, contamination risk, and regulatory context can change expectations. |
| High-throughput screening assays | 96-, 384-, or 1536-well screening, primary screening, counter-screening, hit confirmation | Assay robustness, automation compatibility, false positives, and statistical quality metrics are central. |
The category tells the sponsor where to start. It does not prove that a CRO is the right fit.
The Same Assay Name Can Mean Different Things
One reason CRO selection is difficult is that assay names are broad.
For example, ELISA may mean a simple commercial kit, a custom ligand-binding assay, a cytokine panel, a bridging ADA assay, a PK assay, or a biomarker assay in a difficult matrix. The same word does not define the complexity.
Flow cytometry may mean a simple surface-marker panel, intracellular staining, phospho-flow, immune phenotyping, receptor occupancy, cell sorting, rare-cell detection, or functional immune profiling.
LC-MS may mean impurity profiling, intact mass analysis, peptide mapping, small-molecule quantification, metabolomics, glycation analysis, proteomics, or bioanalytical PK support.
Cell-based assay may mean a reporter cell line, a primary-cell functional assay, a co-culture system, an organoid model, a cytotoxicity assay, or a potency assay for a biologic.
A CRO may be excellent in one version and weak in another.
The sponsor should not ask only, “Do you offer this assay?”
The better question is:
Have you performed this assay type for this molecule class, sample type, biological context, and intended use?
NCBI BioAssay Shows the Scale and Diversity of Assay Biology
The PubChem BioAssay resource, hosted by NCBI, is useful because it shows how broad the assay universe really is. PubChem BioAssay contains bioactivity and toxicity data from contributing organizations and supports research in medicinal chemistry, drug discovery, pharmaceutical genomics, and informatics.
For Project Sponsors, the lesson is not that PubChem BioAssay replaces CRO selection. It does not. PubChem BioAssay is a data archive and discovery resource, not a CRO vendor marketplace.
The lesson is that assays are diverse, contextual, and data-rich. BioAssay records can include tested substances, biological targets, assay descriptions, data tables, annotations, and related assays. That kind of structured assay context matters because assay results are not meaningful without knowing what was tested, how it was tested, what controls were used, and how the result was interpreted.
In CRO outsourcing, the same principle applies. A sponsor should not treat an assay name as enough information. The project context matters.
Pharmacopeial Assays Are Different From Exploratory Assays
Some assays are exploratory. Others are compendial, validated, or quality-control oriented.
A pharmacopeial assay is linked to recognized pharmacopeial standards, such as USP, Ph. Eur., or other compendial systems. These tests may relate to identity, purity, potency, strength, quality, safety, or performance of drug substances, drug products, excipients, biologics, or related materials.
USP General Chapter <1033> describes biological assays as an important part of quality assessment for many biological and some non-biological drug products. USP <1225> and ICH Q2(R2) address validation concepts for analytical procedures, including factors such as specificity or selectivity, accuracy, precision, range, and robustness.
This matters because a CRO that is strong in exploratory assay development may not be the right CRO for a compendial, quality-control, potency, or release-support assay.
The opposite is also true. A CRO that is excellent in routine compendial testing may not be the best partner for novel mechanism-of-action biology, complex primary-cell assays, or early assay invention.
The right CRO depends on the assay’s intended use.
Current Protocols Helps Show Why Assays Are More Than Names
Current Protocols is a widely used collection of step-by-step research methods and practical overviews across life-science fields. It is useful because it shows how experimental methods require detailed conditions, reagents, controls, timing, troubleshooting, and interpretation.
For outsourcing, the lesson is simple: a protocol is not the same as an assay capability.
A CRO may say it can run a method. But the real question is whether the CRO has the operational experience to run that method reliably for the sponsor’s specific sample, molecule, disease area, and decision point.
A protocol can describe a method. A capable CRO must execute it with the right controls, documentation, reproducibility, and scientific judgment.
This difference is critical when the assay involves unstable samples, primary cells, biologics, complex matrices, low-abundance analytes, live-cell readouts, image analysis, or multi-step workflows.
Assay Complexity Increases With Molecule Type and Modality
The right assay depends heavily on the therapeutic modality.
A small molecule, monoclonal antibody, bispecific antibody, peptide, protein therapeutic, RNA therapy, gene therapy, cell therapy, vaccine, diagnostic product, microbiome product, or biomarker program may require different assay logic.
| Modality or product type | Assay complexity to consider |
|---|---|
| Small molecules | Enzyme inhibition, target engagement, ADME, CYP, transporter, metabolite, PK, toxicology, impurity testing |
| Antibodies and biologics | Binding, potency, aggregation, purity, charge variants, glycosylation, Fc function, ADA, PK, stability |
| Bispecifics and multispecifics | Dual binding, avidity, functional bridging, cell engagement, cytokine release, developability, manufacturability |
| Cell therapies | Cell phenotype, potency, viability, identity, exhaustion markers, cytokine release, killing assays, persistence markers |
| Gene therapies | Vector titer, potency, transduction efficiency, biodistribution, immunogenicity, residual impurities, expression readout |
| RNA therapeutics | RNA integrity, delivery efficiency, knockdown, off-target effects, immunostimulation, tissue distribution |
| Diagnostics and biomarkers | Sensitivity, specificity, analytical validity, clinical context, cutoff, reproducibility, matrix effects |
A CRO may be strong in small-molecule ADME but weak in biologics potency. Another may be excellent in antibody characterization but not in cell-therapy functional assays. Another may run NGS workflows but not provide clinical-grade interpretation or complex bioinformatics.
Assay fit is modality-specific.
Therapeutic Area Also Changes the Assay Requirement
The same assay platform can behave differently across therapeutic areas.
An oncology assay may require tumor-cell models, immune co-culture, spheroids, organoids, xenograft tissue, or biomarker panels. An immunology project may require primary immune cells, cytokine readouts, receptor occupancy, activation markers, or inflammation models. A CNS project may involve neuronal cells, BBB models, synaptic readouts, or specialized animal models. Infectious disease work may require biosafety expertise, pathogen-specific methods, neutralization assays, or microbiology infrastructure.
A CRO that is technically competent in a method may still be weak in the therapeutic context.
This is especially important when data interpretation depends on disease biology, not only assay execution.
A sponsor should not only ask:
Can this CRO run the assay?
The sponsor should ask:
Can this CRO run the assay in the biological context that matters for this project?
Data Quality Depends on Assay Fit, Not Only Laboratory Skill
Good laboratory technique is necessary, but not sufficient.
Data quality depends on the relationship between the assay and the decision.
A high-quality assay should be fit for purpose. It should have appropriate controls, sensitivity, specificity or selectivity, precision, dynamic range, reproducibility, robustness, and documentation relative to the intended use.
For high-throughput screening, the Assay Guidance Manual describes statistical tools used for assay performance validation in 96-, 384-, and 1536-well formats. The Z-factor and related metrics are used to evaluate assay quality and robustness in screening contexts.
For bioanalytical assays, FDA and ICH M10 guidance focuses on validation and study sample analysis for chromatographic and ligand-binding assays used to measure drugs and active metabolites in nonclinical and clinical subjects.
For analytical procedures, ICH Q2(R2) and USP validation chapters emphasize that methods must be evaluated for performance characteristics appropriate to their intended analytical use.
The shared principle is clear:
An assay is only useful if it is suitable for its intended purpose.
Wrong Assay Selection Can Create Misleading Confidence
A weak assay does not always fail obviously. Sometimes it produces clean-looking data that are not biologically or analytically meaningful.
That is dangerous.
A sponsor may receive a report with graphs, statistics, and conclusions, but the assay may have been poorly suited to the molecule or question. The result may look professional while still being misleading.
Examples include:
-
A binding assay that does not reflect functional activity
-
A cell-line assay that does not model the relevant biology
-
A potency assay that is precise but not biologically meaningful
-
A biomarker assay with matrix interference
-
A screening assay with high false-positive or false-negative risk
-
A genomics assay with poor sample QC or weak bioinformatics interpretation
-
A stability assay that does not match real storage or formulation risk
-
A toxicology endpoint that does not align with the expected mechanism of risk
The consequence is not only wasted money. The sponsor may make the wrong decision with confidence.
That is worse than knowing the data are weak.
Each CRO Has an Assay “Center of Gravity”
CROs are not interchangeable. Each CRO has a center of gravity.
Some are strongest in routine analytical testing. Some are strongest in early discovery biology. Some specialize in bioanalysis. Some are built around toxicology. Some focus on CMC support. Some are excellent in immunology assays, flow cytometry, or cytokine panels. Some are strong in genomics or bioinformatics. Some are better for biologics. Some are better for small molecules. Some are excellent at high-throughput screening, but not custom assay development.
This is normal. It is not a weakness.
The problem begins when sponsors expect one CRO to be equally strong in every assay.
A strong outsourcing strategy recognizes that assay expertise is specialized. The best CRO for one assay may not be the best CRO for the next assay in the same program.
InnoEco is designed around this reality. The platform helps Project Sponsors compare CRO partners by structured assay capabilities, technical fit, therapeutic context, modality relevance, and project needs.
How InnoEco Helps Sponsors Match Assays With the Right CRO Expertise
InnoEco is designed to improve CRO discovery and assay-fit matching.
Instead of treating CROs as generic vendors, InnoEco helps organize provider information around scientific services, assay platforms, modality experience, therapeutic area, quality scope, geography, delivery capacity, and project context.
This helps Project Sponsors ask more useful questions:
-
Which CROs have relevant assay expertise?
-
Which CROs understand the molecule or modality?
-
Which CROs have experience in the therapeutic area?
-
Which CROs can support the intended use of the data?
-
Which CROs can provide the right level of documentation?
-
Which CROs can manage the timeline and deliverable expectations?
InnoEco does not replace scientific judgment, assay validation, quality agreements, sponsor oversight, or expert review. It helps make the selection process more structured before the project begins.
That structure matters because the assay is often the bridge between a scientific idea and a development decision.
InnoEco’s View: The Right Assay and the Right CRO Must Be Chosen Together
A good CRO match is not only about company reputation, price, or availability. It is about whether the CRO can generate the right data from the right assay for the right decision.
The assay and the CRO must be evaluated together.
A strong assay in the wrong lab can fail. A strong CRO using the wrong assay can produce unusable data. A technically correct assay used for the wrong decision can mislead the sponsor.
For Project Sponsors, the goal is not to outsource a task. The goal is to generate reliable evidence.
InnoEco’s position is simple:
Assay fit, CRO expertise, and data quality are inseparable.
When those three elements are aligned, outsourcing becomes more useful. When they are separated, CRO projects become expensive experiments in miscommunication.
FAQ
What types of assays do CROs provide?
CROs may provide biochemical, biophysical, cell-based, phenotypic, immunoassay, bioanalytical, ADME, DMPK, toxicology, analytical, CMC, potency, genomics, biomarker, microbiology, and high-throughput screening assays. The exact coverage depends on the CRO.
Can one CRO perform every type of assay?
Usually no. CROs often specialize in specific assay categories, technologies, modalities, therapeutic areas, or development stages. A CRO that is excellent in one assay family may not be the best partner for another.
Why is assay selection important in CRO outsourcing?
Assay selection affects data quality, interpretation, timeline, cost, and downstream development decisions. The wrong assay can produce data that are technically generated but not useful for the sponsor’s question.
What is NCBI BioAssay?
NCBI-hosted PubChem BioAssay is a public resource containing bioactivity and toxicity assay data from contributing organizations. It helps show the diversity of assay formats and biological readouts, but it is not a CRO selection platform.
What are pharmacopeial assays?
Pharmacopeial assays are tests connected to recognized compendial standards, such as USP or other pharmacopeias. They may relate to identity, quality, purity, potency, strength, safety, or performance, depending on the product and method.
How does InnoEco help with assay-based CRO selection?
InnoEco helps Project Sponsors compare CRO partners by structured assay capabilities, technical expertise, therapeutic area, modality fit, quality scope, timeline, and project context. This supports better matching between the assay need and CRO expertise.
References
- [1] PubChem / NCBI. PubChem BioAssay documentation and BioAssay database description.
- [2] Wang Y, et al. PubChem’s BioAssay Database. Nucleic Acids Research. 2011.
- [3] U.S. Pharmacopeia. USP General Chapter <1033>, Biological Assay Validation.
- [4] U.S. Pharmacopeia. USP General Chapter <1225>, Validation of Compendial Procedures.
- [5] International Council for Harmonisation. ICH Q2(R2), Validation of Analytical Procedures.
- [6] U.S. Food and Drug Administration / ICH. M10 Bioanalytical Method Validation and Study Sample Analysis.
- [7] Markossian S, et al. Assay Guidance Manual. NCBI Bookshelf.
- [8] Iversen PW, et al. HTS Assay Validation. Assay Guidance Manual, NCBI Bookshelf.
- [9] Zhang JH, Chung TDY, Oldenburg KR. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of Biomolecular Screening. 1999.
- [10] Wiley. Current Protocols collection and Current Protocols in Molecular Biology.